Balveen Kaur

UNVERIFIED PROFILE

Are you Balveen Kaur?   Register this Author

Register author

Balveen Kaur

Publications by authors named "Balveen Kaur"

Are you Balveen Kaur?   Register this Author

97Publications

-Reads

PRMT5 as a druggable target for glioblastoma therapy.

Neuro Oncol 2018 May;20(6):753-763

The Vivian L. Smith Department of Neurosurgery, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas.

View Article
May 2018

Complex role of NK cells in regulation of oncolytic virus-bortezomib therapy.

Proc Natl Acad Sci U S A 2018 May 23;115(19):4927-4932. Epub 2018 Apr 23.

Mathematical Biosciences Institute, The Ohio State University, Columbus, OH 43210;

View Article
May 2018

RNA Nanoparticle-Based Targeted Therapy for Glioblastoma through Inhibition of Oncogenic miR-21.

Mol Ther 2017 Jul 18;25(7):1544-1555. Epub 2017 Jan 18.

Department of Cancer Biology and Genetics, College of Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA. Electronic address:

View Article
July 2017

The Fc Domain of Immunoglobulin Is Sufficient to Bridge NK Cells with Virally Infected Cells.

Immunity 2017 07;47(1):159-170.e10

The Ohio State University Comprehensive Cancer Center, The James Cancer Hospital and Solove Research Institute, Columbus, OH 43210, USA; Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH 43205, USA. Electronic address:

View Article
July 2017

Sex as a biological variable in response to temozolomide.

Neuro Oncol 2017 06;19(6):873-874

Department of Neurological Surgery, Dardinger Laboratory for Neuro-oncology and Neurosciences, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.

View Article
June 2017

Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma.

Mol Ther Oncolytics 2017 Jun 10;5:87-96. Epub 2017 May 10.

Department of Otolaryngology-Head and Neck Surgery, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH 43210, USA.

View Article
June 2017

Humanized chondroitinase ABC sensitizes glioblastoma cells to temozolomide.

J Gene Med 2017 Mar;19(3)

Department of Neurological Surgery, The Ohio State University Comprehensive Cancer Center, The James Cancer Hospital, and Solove Research Institute, Columbus, OH, USA.

View Article
March 2017

Inhibition of SOAT1 Suppresses Glioblastoma Growth via Blocking SREBP-1-Mediated Lipogenesis.

Clin Cancer Res 2016 Nov 8;22(21):5337-5348. Epub 2016 Jun 8.

Department of Radiation Oncology, James Comprehensive Cancer Center & Arthur G James Cancer Hospital, The Ohio State Medical Center, Columbus, Ohio.

View Article
November 2016

Bortezomib Treatment Sensitizes Oncolytic HSV-1-Treated Tumors to NK Cell Immunotherapy.

Clin Cancer Res 2016 Nov 7;22(21):5265-5276. Epub 2016 Jul 7.

Department of Neurological Surgery, Dardinger Laboratory for Neuro-oncology and Neurosciences, The Ohio State University Wexner Medical Center, Columbus, Ohio.

View Article
November 2016

Feedback Loop Regulation of SCAP/SREBP-1 by miR-29 Modulates EGFR Signaling-Driven Glioblastoma Growth.

Cell Rep 2016 08 28;16(6):1527-1535. Epub 2016 Jul 28.

Department of Radiation Oncology, James Comprehensive Cancer Center, College of Medicine, The Ohio State University, Columbus, OH 43210, USA. Electronic address:

View Article
August 2016

The current status of oncolytic viral therapy for head and neck cancer.

World J Otorhinolaryngol Head Neck Surg 2016 Jun 22;2(2):84-89. Epub 2016 Jul 22.

Department of Otolaryngology - Head and Neck Surgery, The James Cancer Hospital and Solove Research Institute, Wexner Medical Center at The Ohio State University, USA.

View Article
June 2016

ATN-224 enhances antitumor efficacy of oncolytic herpes virus against both local and metastatic head and neck squamous cell carcinoma.

Mol Ther Oncolytics 2015 20;2:15008. Epub 2015 May 20.

Department of Otolaryngology-Head and Neck Surgery, The James Cancer Hospital and Solove Research Institute, Wexner Medical Center at The Ohio State University , Columbus, Ohio, USA.

View Article
April 2016

Nanofiber-based paramagnetic probes for rapid, real-time biomedical oximetry.

Biomed Microdevices 2016 Apr;18(2):38

Department of Physics, The Ohio State University, 191West Woodruff Avenue, Physics Research Building, Columbus, OH, 43210, USA.

View Article
April 2016

How to train glioma cells to die: molecular challenges in cell death.

J Neurooncol 2016 Feb 5;126(3):377-84. Epub 2015 Nov 5.

Department of Neurological Surgery, The Ohio State University Medical Center, 385-B OSUCCC, 410 West 12th Avenue, Columbus, OH, 43210, USA.

View Article
February 2016

Standardized orthotopic xenografts in zebrafish reveal glioma cell-line-specific characteristics and tumor cell heterogeneity.

Dis Model Mech 2016 Feb 10;9(2):199-210. Epub 2015 Dec 10.

Department of Neuroscience, The Ohio State University College of Medicine, Columbus, OH 43210, USA

View Article
February 2016

Functional assays for specific targeting and delivery of RNA nanoparticles to brain tumor.

Methods Mol Biol 2015 ;1297:137-52

Department of MolecularVirology, Immunologyand Medical Genetics, Comprehensive Cancer Center, The Ohio State University, 1080 Biomedical Research Tower, 460 W. 12th Ave., Columbus, OH, 43210, USA.

View Article
January 2016

TGFβ Treatment Enhances Glioblastoma Virotherapy by Inhibiting the Innate Immune Response.

Cancer Res 2015 Dec 2;75(24):5273-82. Epub 2015 Dec 2.

Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, Ohio. The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.

View Article
December 2015

Glucose-Mediated N-glycosylation of SCAP Is Essential for SREBP-1 Activation and Tumor Growth.

Cancer Cell 2015 Nov;28(5):569-581

Department of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA. Electronic address:

View Article
November 2015

The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment.

Clin Cancer Res 2015 Jul 31;21(14):3274-85. Epub 2015 Mar 31.

Department of Neurological Surgery, James Comprehensive Cancer Center, The Ohio State University Medical Center, Columbus, Ohio.

View Article
July 2015

CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells.

Sci Rep 2015 Jul 9;5:11483. Epub 2015 Jul 9.

1] Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, Ohio 43210, USA [2] The Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210, USA.

View Article
July 2015

Effects of CCN1 and Macrophage Content on Glioma Virotherapy: A Mathematical Model.

Bull Math Biol 2015 Jun 11;77(6):984-1012. Epub 2015 Mar 11.

Mathematical Biosciences Institute, The Ohio State University, Columbus, OH, 43210, USA,

View Article
June 2015

RNA nanoparticle as a vector for targeted siRNA delivery into glioblastoma mouse model.

Oncotarget 2015 Jun;6(17):14766-76

Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.

View Article
June 2015

In vivo brain electrophoresis - a novel method for chemotherapy of CNS diseases.

Expert Opin Drug Deliv 2015 May 10;12(5):727-34. Epub 2015 Feb 10.

The Ohio State University Wexner Medical Center, Department of Neurological Surgery , N-1025 Doan Hall, 410 west 10th ave, Columbus, OH 43210 , USA +1 614 293 1970 ; +1 614 293 4024 ;

View Article
May 2015

Choindroitinase ABC I-mediated enhancement of oncolytic virus spread and anti tumor efficacy: a mathematical model.

PLoS One 2014 21;9(7):e102499. Epub 2014 Jul 21.

Department of Mathematics, Ohio State University, Columbus, Ohio, United States of America; Mathematical Biosciences Institute, Ohio State University, Columbus, Ohio, United States of America.

View Article
April 2015

Use of miRNA response sequences to block off-target replication and increase the safety of an unattenuated, glioblastoma-targeted oncolytic HSV.

Mol Ther 2015 Jan 9;23(1):99-107. Epub 2014 Sep 9.

1] Department of Microbiology and Molecular Genetics, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA [2] Department of Neurological Surgery, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA [3] SVeB University of Ferrara, Ferrara, Italy.

View Article
January 2015

Changes in BAI1 and nestin expression are prognostic indicators for survival and metastases in breast cancer and provide opportunities for dual targeted therapies.

Mol Cancer Ther 2015 Jan 5;14(1):307-14. Epub 2014 Nov 5.

Department of Neurological Surgery, James Comprehensive Cancer Center, The Ohio State University Medical Center, Columbus, Ohio. Department of Radiation Oncology, James Comprehensive Cancer Center, The Ohio State University Medical Center, Columbus, Ohio.

View Article
January 2015

Doxorubicin synergizes with 34.5ENVE to enhance antitumor efficacy against metastatic ovarian cancer.

Clin Cancer Res 2014 Dec 7;20(24):6479-94. Epub 2014 Oct 7.

Dardinger Laboratory for Neuro-oncology and Neurosciences, Department of Neurological Surgery, The Ohio State University, Columbus, Ohio.

View Article
December 2014

Piperlongumine treatment inactivates peroxiredoxin 4, exacerbates endoplasmic reticulum stress, and preferentially kills high-grade glioma cells.

Neuro Oncol 2014 Oct 30;16(10):1354-64. Epub 2014 May 30.

Dardinger Neuro-oncology Center, Department of Neurological Surgery, Ohio State University, Columbus, Ohio (T.H.K., J.S., S.-H.K., A.K.P., I.N., B.K., C.-H.K.); Solid Tumor Program at the James Comprehensive Cancer Center, Columbus, Ohio (T.H.K., J.S., A.K.P., C.-H.K.); Center for Biostatistics, Ohio State University, Columbus, Ohio (X.M.); Department of Radiation Oncology, Ohio State University, Columbus, Ohio (K.P.); Division of Hematology, Department of Internal Medicine, Ohio State University, Columbus, Ohio (J.Y.); Department of Molecular and Cellular Biochemistry, Ohio State University Wexner Medical Center, Columbus, Ohio (S.O.Y.).

View Article
October 2014

Aurora-A inhibition offers a novel therapy effective against intracranial glioblastoma.

Cancer Res 2014 Oct 8;74(19):5364-70. Epub 2014 Aug 8.

Department of Pathology, The Ohio State University, Columbus Ohio. Department of Neuroscience, The Ohio State University, Columbus Ohio.

View Article
October 2014

FHIT suppresses epithelial-mesenchymal transition (EMT) and metastasis in lung cancer through modulation of microRNAs.

PLoS Genet 2014 Oct 23;10(10):e1004652. Epub 2014 Oct 23.

Department of Molecular Virology, Immunology and Medical Genetics, and Comprehensive Cancer Center, Ohio State University, Columbus, Ohio, United States of America.

View Article
October 2014

Role of cysteine-rich 61 protein (CCN1) in macrophage-mediated oncolytic herpes simplex virus clearance.

Mol Ther 2014 Sep 4;22(9):1678-87. Epub 2014 Jun 4.

Department of Neurological Surgery, Dardinger Laboratory for Neuro-oncology and Neurosciences, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.

View Article
September 2014

Thymoquinone inhibits autophagy and induces cathepsin-mediated, caspase-independent cell death in glioblastoma cells.

PLoS One 2013 9;8(9):e72882. Epub 2013 Sep 9.

Department of Radiology, The Ohio State University Wexner Medical Center, Columbus, Ohio, United States of America.

View Article
June 2014

In vivo optical imaging of brain tumors and arthritis using fluorescent SapC-DOPS nanovesicles.

J Vis Exp 2014 May 2(87). Epub 2014 May 2.

Division of Hematology-Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine; Division of Human Genetics, University of Cincinnati College of Medicine;

View Article
May 2014

STAT3 activation promotes oncolytic HSV1 replication in glioma cells.

PLoS One 2013 2;8(8):e71932. Epub 2013 Aug 2.

Dardinger Center for Neuro-Oncology and Neurosciences, Department of Neurological Surgery, James Cancer Hospital/Solove Research Institute, the Ohio State University, Columbus, Ohio, United States of America.

View Article
April 2014

Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma.

Cancer Res 2014 Mar 22;74(6):1752-65. Epub 2014 Jan 22.

Authors' Affiliations: Division of Hematology, Department of Internal Medicine; Division of Infectious Diseases, Department of Internal Medicine; Departments of Neurosurgery; Molecular and Cellular Biochemistry; Chemical Engineering; Statistics; Pathology; Radiation Oncology; and College of Pharmacy, The Ohio State University (OSU), Columbus; Case Comprehensive Cancer Center; and Department of Epidemiology and Biostatistics, CWRU School of Medicine, Cleveland, Ohio.

View Article
March 2014

How efficient are autophagy inhibitors as treatment for glioblastoma?

CNS Oncol 2014 Jan;3(1):5-7

Dardinger Laboratory for Neuro-oncology & Neurosciences, Department of Neurological Surgery, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.

View Article
January 2014

Gene expression profiling of the anti-glioma effect of Cilengitide.

Springerplus 2013 Dec 15;2(1):160. Epub 2013 Apr 15.

Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1, Shikata-cho, Kita-ku, Okayama, 700-8558 Japan.

View Article
December 2013

DNA demethylating agents synergize with oncolytic HSV1 against malignant gliomas.

Clin Cancer Res 2013 Nov 20;19(21):5952-9. Epub 2013 Sep 20.

Authors' Affiliations: Dardinger Center for Neuro-oncology and Neurosciences, Department of Neurological Surgery, James Cancer Hospital/Solove Research Institute/Comprehensive Cancer Center and Wexner Medical Center; Center for Biostatistics, The Ohio State University, Columbus, Ohio; and Department of Neurosurgery Institute for the Neurosciences at the Brigham, Brigham and Women's/Faulkner Hospital and Center for Neuro-oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article
November 2013

Systemic delivery of SapC-DOPS has antiangiogenic and antitumor effects against glioblastoma.

Mol Ther 2013 Aug 4;21(8):1517-25. Epub 2013 Jun 4.

Dardinger Laboratory for Neuro-oncology and Neurosciences, Department of Neurological Surgery, The Ohio State University Medical Center, Columbus, Ohio 43210, USA.

View Article
August 2013

Brain-specific angiogenesis inhibitor-1 signaling, regulation, and enrichment in the postsynaptic density.

J Biol Chem 2013 Aug 19;288(31):22248-56. Epub 2013 Jun 19.

Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia 30322, USA.

View Article
August 2013

Cytomegalovirus contributes to glioblastoma in the context of tumor suppressor mutations.

Cancer Res 2013 Jun;73(11):3441-50

Department of Neurological Surgery, Dardinger Neuro-oncology Center, Solid Tumor Program at the James Comprehensive Cancer Center, Center for Biostatistics, Departments of Pathology, Veterinary Biosciences, and Surgery, The Ohio State University Medical Center, Columbus, Ohio, USA.

View Article
June 2013

Bimodal anti-glioma mechanisms of cilengitide demonstrated by novel invasive glioma models.

Neuropathology 2013 Apr 19;33(2):162-74. Epub 2012 Sep 19.

Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

View Article
April 2013

Anti-angiogenic gene therapy in the treatment of malignant gliomas.

Neurosci Lett 2012 Oct 10;527(2):62-70. Epub 2012 Aug 10.

Dardinger Center for Neuro-oncology and Neurosciences, N-1017 Doan Hall, 410 W. 10th Avenue, James Cancer Hospital/Solove Research Institute and The Ohio State University Wexner Medical Center, Columbus, OH 43210-1240, USA.

View Article
October 2012

Deciphering the Multifaceted Relationship between Oncolytic Viruses and Natural Killer Cells.

Adv Virol 2012 11;2012:702839. Epub 2011 Dec 11.

Medical Scientist Training Program, The Ohio State University, Columbus, OH 43210, USA.

View Article
August 2012

Extracellular vesicles and their convergence with viral pathways.

Adv Virol 2012 25;2012:767694. Epub 2012 Jul 25.

Departments of Neurology and Radiology, Massachusetts General Hospital and Neuroscience Program, Harvard Medical School, Boston, MA 02129, USA.

View Article
August 2012

Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress.

Curr Pharm Biotechnol 2012 Jul;13(9):1842-51

Dardinger Laboratory for Neuro-oncology and Neurosciences, Department of Neurological Surgery, James Comprehensive Cancer Center and The Ohio State University Medical Center, Columbus, Ohio, USA.

View Article
July 2012

MicroRNAs/TP53 feedback circuitry in glioblastoma multiforme.

Proc Natl Acad Sci U S A 2012 Apr 19;109(14):5316-21. Epub 2012 Mar 19.

Department of Molecular Virology, Immunology, and Medical Genetics, Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210, USA.

View Article
April 2012

Extracellular matrix protein CCN1 limits oncolytic efficacy in glioma.

Cancer Res 2012 Mar 26;72(6):1353-62. Epub 2012 Jan 26.

Dardinger Laboratory for Neuro-oncology and Neurosciences, Department of Neurological Surgery, The Ohio State University Medical Center, Columbus, Ohio, USA.

View Article
March 2012

Antitumor efficacy of 34.5ENVE: a transcriptionally retargeted and "Vstat120"-expressing oncolytic virus.

Mol Ther 2012 Feb 25;20(2):287-97. Epub 2011 Oct 25.

Department of Neurological Surgery, Dardinger Laboratory for Neuro-oncology and Neurosciences, The Ohio State University Medical Center, Columbus, Ohio 43210, USA.

View Article
February 2012

Indirubins decrease glioma invasion by blocking migratory phenotypes in both the tumor and stromal endothelial cell compartments.

Cancer Res 2011 Aug 22;71(16):5374-80. Epub 2011 Jun 22.

Dardinger Laboratory for Neuro-oncology and Neurosciences, Department of Neurological Surgery, The Ohio State University Medical Center and James Comprehensive Cancer Center, Columbus, Ohio 43210, USA.

View Article
August 2011

Chondroitinase ABC I-mediated enhancement of oncolytic virus spread and antitumor efficacy.

Clin Cancer Res 2011 Mar 21;17(6):1362-72. Epub 2010 Dec 21.

Dardinger Laboratory for Neuro-oncology and Neurosciences, Department of Neurological Surgery, Center for Biostatistics, The Ohio State University Medical Center, Columbus, Ohio, USA.

View Article
March 2011

Directing systemic oncolytic viral delivery to tumors via carrier cells.

Cytokine Growth Factor Rev 2010 Apr-Jun;21(2-3):119-26. Epub 2010 Mar 11.

Dardinger Laboratory for Neuro-oncology and Neurosciences, Department of Neurological Surgery, James Comprehensive Cancer Center, Columbus, OH 43210, United States.

View Article
September 2010

Impact of tumor microenvironment on oncolytic viral therapy.

Cytokine Growth Factor Rev 2010 Apr-Jun;21(2-3):127-34

Dardinger Laboratory for Neuro-oncology and Neurosciences, Department of Neurological Surgery, James Comprehensive Cancer Center, Columbus, OH 43210, United States.

View Article
September 2010

Histidine-rich glycoprotein modulates the anti-angiogenic effects of vasculostatin.

Am J Pathol 2010 Apr 18;176(4):2039-50. Epub 2010 Feb 18.

Department of Cell Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.

View Article
April 2010

Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1.

Mol Ther 2010 Feb 20;18(2):285-94. Epub 2009 Oct 20.

Dardinger Laboratory for Neuro-oncology and Neurosciences, Department of Neurological Surgery, James Comprehensive Cancer Center and The Ohio State University Medical Center, Columbus, Ohio 43210, USA.

View Article
February 2010

"Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment.

Curr Gene Ther 2009 Oct;9(5):341-55

Dardinger Laboratory for Neuro-oncology and Neurosciences, Department of Neurological Surgery, James Comprehensive Cancer Center and The Ohio State University Medical Center, 400 West 12th Avenue, Columbus, OH 43210,USA.

View Article
October 2009

Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas.

J Neurooncol 2009 Sep 21;94(3):299-312. Epub 2009 Apr 21.

Department of Pathology, The Ohio State University, 165 Hamilton Hall, Columbus, OH 43210, USA.

View Article
September 2009

Pharmacologic and chemical adjuvants in tumor virotherapy.

Chem Rev 2009 Jul;109(7):3125-40

Dardinger Laboratory for Neuro-oncology and Neurosciences, Department of Neurological Surgery, James Comprehensive Cancer Center and The Ohio State University Medical Center, Columbus, Ohio, USA.

View Article
July 2009

Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism.

Cancer Res 2009 Feb 27;69(3):1212-20. Epub 2009 Jan 27.

Department of Neurosurgery, Laboratory of Molecular Neuro-Oncology, Winship Cancer Institute, Emory University, School of Medicine, Atlanta, Georgia 30322, USA.

View Article
February 2009

Advances in oncolytic virus therapy for glioma.

Recent Pat CNS Drug Discov 2009 Jan;4(1):1-13

Dardinger Laboratory for Neuro-oncology and Neurosciences, Department of Neurological Surgery, College of Medicine, The Ohio State University Medical Center, Columbus, OH 43210, USA.

View Article
January 2009

Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61.

Mol Ther 2008 Aug 10;16(8):1382-91. Epub 2008 Jun 10.

Dardinger Laboratory for Neuro-oncology and Neurosciences, Department of Neurological Surgery, James Comprehensive Cancer Center, The Ohio State University Medical Center, Columbus, Ohio, USA.

View Article
August 2008

Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy.

J Natl Cancer Inst 2007 Dec 27;99(23):1768-81. Epub 2007 Nov 27.

Dardinger Laboratory for Neuro-oncology and Neurosciences, Department of Neurological Surgery, The Ohio State University, Columbus, OH 43210, USA.

View Article
December 2007

Oncolytic viruses driven by tumor-specific promoters.

Curr Cancer Drug Targets 2007 Mar;7(2):181-9

Dardinger Laboratory for Neuro-Oncology and Neurosciences, Department of Neurological Surgery, The Ohio State University, Columbus, Ohio 43210, USA.

View Article
March 2007

Personalizing oncolytic virotherapy?

Mol Ther 2007 Jan;15(1):6-7

Dardinger Laboratory for Neuro-oncology and Neurosciences, Comprehensive Cancer Center, and Department of Neurological Surgery, The Ohio State University Medical Center, Columbus, Ohio, USA.

View Article
January 2007

Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses.

Proc Natl Acad Sci U S A 2006 Aug 14;103(34):12873-8. Epub 2006 Aug 14.

Dardinger Center for Neuro-Oncology and Neurosciences, Department of Neurological Surgery, James Cancer Hospital and Solove Research Institute, Ohio State University Medical Center, Columbus, OH 43210, USA.

View Article
August 2006

Gene therapeutics: the future of brain tumor therapy?

Expert Rev Anticancer Ther 2006 Jul;6(7):1053-64

Dardinger Laboratory for Neuro-Oncology and Neurosciences, Department of Neurological Surgery and Comprehensive Cancer Center, The Ohio State University Medical Center, 410 West 12th Avenue, Columbus, OH 43210, USA.

View Article
July 2006

Vasculostatin, a proteolytic fragment of brain angiogenesis inhibitor 1, is an antiangiogenic and antitumorigenic factor.

Oncogene 2005 May;24(22):3632-42

Laboratory of Molecular Neuro-Oncology, Departments of Neurosurgery, Hematology/Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA.

View Article
May 2005

Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis.

Neuro Oncol 2005 Apr;7(2):134-53

Laboratory of Molecular Neuro-Oncology, Department of Neurosurgery and Hematology/Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA.

View Article
April 2005

Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors.

Clin Cancer Res 2004 Dec;10(24):8603-12

Laboratory of Molecular Neuro-Oncology, Department of Neurosurgery, Emory University, Atlanta, Georgia 30322, USA.

View Article
December 2004

Genetic and hypoxic regulation of angiogenesis in gliomas.

J Neurooncol 2004 Nov;70(2):229-43

Laboratory of Molecular Neuro-Oncology, Department of Neuro-surgery and Hematology/Oncology, and Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA.

View Article
November 2004

Genetic modulation of hypoxia induced gene expression and angiogenesis: relevance to brain tumors.

Front Biosci 2003 Jan 1;8:d100-16. Epub 2003 Jan 1.

Department of Pathology and Laboratory Medicine and Laboratory of Molecular Neuro-Oncology, Emory University School of Medicine, Atlanta, GA, USA.

View Article
January 2003

Brain angiogenesis inhibitor 1 is differentially expressed in normal brain and glioblastoma independently of p53 expression.

Am J Pathol 2003 Jan;162(1):19-27

Laboratory of Molecular Neuro-Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia 30322, USA.

View Article
January 2003

Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells.

Cancer Res 2002 May;62(9):2478-82

Winship Cancer Institute, Department of Hematology and Oncology, Emory University School of Medicine, Atlanta, Georgia 30322, USA.

View Article
May 2002

Initiation of human astrocytoma by clonal evolution of cells with progressive loss of p53 functions in a patient with a 283H TP53 germ-line mutation: evidence for a precursor lesion.

Cancer Res 2002 May;62(10):2897-905

Laboratory of Molecular Neuro-Oncology, Department of Neurosurgery and Winship Cancer Institute, Emory University School of Medicine, 1365B Clifton Road, Atlanta, GA 30322, USA.

View Article
May 2002

Genetic and biologic progression in astrocytomas and their relation to angiogenic dysregulation.

Adv Anat Pathol 2002 Jan;9(1):24-36

Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.

View Article
January 2002